Form 4: Aquestive Therapeutics SVP Receives 25,000 Shares of Restricted Stock

Sherry Korczynski, SVP of Sales and Marketing at Aquestive Therapeutics, acquired 25,000 shares of restricted common stock on June 7, 2024, which will vest in three annual installments.

Summary

• Sherry Korczynski, SVP of Sales and Marketing at Aquestive Therapeutics, acquired 25,000 shares of restricted common stock on June 7, 2024.
• The stock was acquired at a price of $0.
• The shares will vest in three annual installments: 25% on the first installment, 25% on the second installment, and 50% on the third installment.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a transaction. The sentiment is slightly positive as it indicates continued investment in the company by a key executive.

Positives

• The acquisition of restricted stock may align the executive's interests with those of the shareholders.

Industry Context

This type of stock grant is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock grants to senior executives are a common practice across the pharmaceutical industry.
• Companies like Teva Pharmaceutical Industries Ltd. and Mylan N.V. (now Viatris) also use stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedule of three years is fairly standard, aligning with typical retention incentives.

Stakeholder Impact

• The stock grant could potentially align the executive's interests more closely with those of the shareholders.

Key Dates